Halozyme Therapeutics (HALO) Change in Accured Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Change in Accured Expenses data on file, last reported at -$24.9 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 370.33% year-over-year to -$24.9 million in Q1 2026; TTM through Mar 2026 was -$27.9 million, a 174.43% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, down 86.78% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$24.9 million, down from $33.8 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for HALO reached as high as $50.2 million in Q4 2024 and fell as low as -$29.7 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $2.4 million across 5 years, with a median of -$2.0 million in 2023.
• Across the five-year window, Change in Accured Expenses slumped 3007.67% in 2023 and soared 629.44% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $326000.0 in 2022, then slumped by 3007.67% to -$9.5 million in 2023, then surged by 629.44% to $50.2 million in 2024, then slumped by 32.55% to $33.8 million in 2025, then tumbled by 173.63% to -$24.9 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$24.9 million in Q1 2026, $33.8 million in Q4 2025, and -$7.2 million in Q3 2025.